Blood pressure control in older adults with hypertension: A systematic review with meta-analysis and meta-regression
- PMID: 33447766
- PMCID: PMC7803055
- DOI: 10.1016/j.ijchy.2020.100040
Blood pressure control in older adults with hypertension: A systematic review with meta-analysis and meta-regression
Abstract
Background: Managing blood pressure reduces CVD risk, but optimal treatment thresholds remain unclear as it is a balancing act to avoid hypotension-related adverse events.
Objectives: This systematic review, meta-analysis and meta-regression evaluated the benefits of intensive BP treatment in hypertensive older adults.
Methods: We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library of Controlled Trials until January 31, 2020. Studies comparing different BP treatments/targets and/or active BP against placebo treatment, with a minimum 12 months follow-up, were included. Risk ratios (RR) and 95% CIs were calculated using a random effects model. The primary outcome was RR of major cardiovascular events (MCEs); secondary outcomes included myocardial infarction (MI), stroke, heart failure (HF), cardiovascular (CV) mortality, and all-cause mortality.
Results: We included 16 studies totaling 65,890 hypertensive participants (average age 69.4 years) with a follow-up period from 1.8 to 4.9 years. Intensive BP treatment significantly reduced the relative risk of MCEs by 26% (RR:0.74, 95%CI 0.64-0.86, p = 0.000; I 2 = 79.71%). RR of MI significantly reduced by 13% (RR:0.87, 95%CI 0.76-1.00, p = 0.052; I 2 = 0.00%), stroke by 28% (RR:0.72, 95%CI 0.64-0.82, p = 0.000; I 2 = 32.45%), HF by 47% (RR:0.53, 95% CI 0.43-0.66, p = 0.000; I 2 = 1.23%), and CV mortality by 24% (RR:0.76, 95%CI 0.66-0.89, p = 0.000; I 2 = 39.74%). All-cause mortality reduced by 17% (RR:0.83, 95%CI 0.73-0.93, p = 0.001; I 2 = 53.09%). Of the participants - 61% reached BP targets and 5% withdrew; with 1 hypotension-related event per 780 people treated.
Conclusions: Lower BP treatment targets are optimal for CV protection, effective, well-tolerated and safe, and support the latest hypertension guidelines.
Keywords: BP, blood pressure; Blood pressure treatment targets; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; Cardiovascular events; HF, heart failure; Hypertension; MCE, major cardiovascular event; Mortality; RR, relative risk or risk ratio.
© 2020 The Authors.
Conflict of interest statement
None of the authors declare any conflicts of interest.
Figures
References
-
- Nguyen B., Bauman A., Ding D. Association between lifestyle risk factors and incident hypertension among middle-aged and older Australians. Prev. Med. 2019;118:73–80. - PubMed
-
- Harrap S.B., Lung T., Chalmers J. New blood pressure guidelines pose difficult choices for Australian physicians. Circ. Res. 2019;124(7):975–977. - PubMed
-
- Beckett N.S., Peters R., Fletcher A.E. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008;358(18):1887–1898. - PubMed
-
- Hansson L., Zanchetti A., Carruthers S.G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755–1762. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
